Diurnal Group plc is a United Kingdom-based specialty pharmaceutical company. The Company targets patient needs in chronic endocrine (hormonal) diseases, such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism and hypothyroidism. The Company has two products in late-stage clinical development targeting adrenal disease: Chronocort and Infacort. The Chronocort is to be used for the treatment of congenital adrenal hyperplasia and adrenal insufficiency in adults. The Infacort is to be used for the same conditions in children. The Company has completed pre-clinical studies of its native testosterone replacement formulation for the treatment of male hypogonadism. The Company has also completed an initial formulation development to enable a selection of a suitable technology to generate formulations of triiodothyronine (T3) and thyroxine (T4) for the treatment of hypothyroidism, which will allow the replacement of the normal physiological ratio of T4 to T3.